60 degrees pharmaceuticals, Inc.(SXTP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SXTP 60 degrees pharmaceuticals, Inc.

Not Yet Opened 01-20 16:00:00 EST

2.01

-0.43

-17.62%

盘后2.03

+0.02+1.00%

19:57 EST

High2.38	Low1.90	Vol501.17K
Open2.22	D1 Closing2.44	Amplitude19.67%
Mkt Cap2.13M	Tradable Cap1.82M	Total Shares1.06M
T/O1.09M	T/O Rate55.25%	Tradable Shares907.09K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SXTP","market":"US","secType":"STK","nameCN":"60 degrees pharmaceuticals, Inc.","latestPrice":2.01,"timestamp":1768942800000,"preClose":2.44,"halted":0,"volume":501172,"hourTrading":{"tag":"盘后","latestPrice":2.03,"preClose":2.01,"latestTime":"19:57 EST","volume":17854,"amount":36847.2147,"timestamp":1768957068789,"change":0.02,"changeRate":0.00995,"amplitude":0.134328},"delay":0,"changeRate":-0.17622950819672137,"floatShares":907086,"shares":1057600,"eps":-18.29146,"marketStatus":"Not Yet Opened","change":-0.43,"latestTime":"01-20 16:00:00 EST","open":2.22,"high":2.38,"low":1.9,"amount":1088421.042758,"amplitude":0.196721,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-18.29146,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768986000000},"marketStatusCode":0,"adr":0,"listingDate":1686801600000,"exchange":"NASDAQ","adjPreClose":2.44,"preHourTrading":{"tag":"盘前","latestPrice":2.3,"preClose":2.44,"latestTime":"09:29 EST","volume":61870,"amount":152182.38144,"timestamp":1768919354488,"change":-0.14,"changeRate":-0.057377,"amplitude":0.315574},"postHourTrading":{"tag":"盘后","latestPrice":2.03,"preClose":2.01,"latestTime":"19:57 EST","volume":17854,"amount":36847.2147,"timestamp":1768957068789,"change":0.02,"changeRate":0.00995,"amplitude":0.134328},"volumeRatio":0.417503},"requestUrl":"/m/hq/s/SXTP/wiki","defaultTab":"wiki","newsList":[{"id":"2604910325","title":"60 Degrees Pharmaceuticals Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2604910325","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604910325?lang=en_us&edition=fundamental","pubTime":"2026-01-17 08:50","pubTimestamp":1768611018,"startTime":"0","endTime":"0","summary":"19:50 EST 60 Degrees Pharmaceuticals (SXTP) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/60-degrees-pharmaceuticals-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/60-degrees-pharmaceuticals-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SXTP"],"gpt_icon":0},{"id":"2603600256","title":"BRIEF-60 Degrees Pharmaceuticals, Inc. Announces Approval Of Reverse Stock Split Ratio","url":"https://stock-news.laohu8.com/highlight/detail?id=2603600256","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603600256?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:11","pubTimestamp":1768482714,"startTime":"0","endTime":"0","summary":"BRIEF-60 Degrees Pharmaceuticals, Inc. Announces Approval Of Reverse Stock Split RatioJan 15 (Reuters) - 60 Degrees Pharmaceuticals Inc SXTP.O:60 DEGREES PHARMACEUTICALS, INC. ANNOUNCES APPROVAL OF RE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nTUACXQ3Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTP","SXTPW","BK4007"],"gpt_icon":0},{"id":"2603160060","title":"60 Degrees Pharmaceuticals Announces 1-for-4 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2603160060","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603160060?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:02","pubTimestamp":1768482162,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals Inc.  will implement a 1-for-4 reverse stock split of its common stock, effective January 20, 2026. The move aims to help the company comply with Nasdaq’s minimum bid price requirements. All outstanding shares and related securities will be adjusted accordingly, and trading will continue under the existing ticker symbol.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on January 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL5WVl4m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4007","IE00BGHQF748.EUR","BK4588","SG9999014039.USD","SXTP","LU2095319765.USD","SG9999014013.SGD","BK4112","LU0314104364.USD","LU2210150020.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","NDAQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","BK4585"],"gpt_icon":0},{"id":"2601984213","title":"60 Degrees Pharma outlines growth strategy in investor webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2601984213","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601984213?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:39","pubTimestamp":1767883142,"startTime":"0","endTime":"0","summary":"An announcement from 60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ) is now available. On January 8, 2026, 60 Degrees Pharmaceuticals made available a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/60-degrees-pharma-outlines-growth-strategy-in-investor-webinar?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/60-degrees-pharma-outlines-growth-strategy-in-investor-webinar?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SXTP","BK4007"],"gpt_icon":0},{"id":"2595802657","title":"60 Degrees Pharmaceuticals Launches B-Free Study to Evaluate Tafenoquine for Chronic Babesiosis Fatigue","url":"https://stock-news.laohu8.com/highlight/detail?id=2595802657","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595802657?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:01","pubTimestamp":1767013271,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals Inc. announced the detection of Babesia infection in 24 percent of patients presenting with chronic fatigue, according to a peer-reviewed study conducted by researchers at North Carolina State University and published in Pathogens. The findings support the theory that Babesia infection may prolong recovery times in patients with chronic fatigue. The company also highlighted the ongoing B-Free Chronic Babesiosis Study , which is evaluating the efficacy and safety of the ARAKODA  regimen over 90 days for the resolution of severe fatigue in patients with chronic babesiosis. Results from the B-Free Study have not yet been presented, and the study is currently enrolling participants at the Icahn School of Medicine at Mount Sinai in New York. Tafenoquine is currently approved for malaria prophylaxis in the United States but is not approved for the treatment or prevention of babesiosis.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL22RNRp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTP","LU0314104364.USD","LU2210150020.SGD","SG9999014021.USD","BK4112","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD","SG9999014013.SGD","SG9999014039.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4585","SG9999014005.SGD","BK4007"],"gpt_icon":0},{"id":"2595678044","title":"60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting With Chronic Fatigue in Peer-Reviewed, Sponsored Study at Nc State","url":"https://stock-news.laohu8.com/highlight/detail?id=2595678044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595678044?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:01","pubTimestamp":1767013260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nTUA5Z7YHT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SXTPW","SXTP","BK4007"],"gpt_icon":0},{"id":"2592953303","title":"Geoffrey S. Dow, President and CEO, Acquires Common Shares of 60 Degrees Pharmaceuticals Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2592953303","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592953303?lang=en_us&edition=fundamental","pubTime":"2025-12-17 06:42","pubTimestamp":1765924934,"startTime":"0","endTime":"0","summary":"Geoffrey S. Dow, President and CEO of 60 Degrees Pharmaceuticals Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL6kWF04:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Geoffrey S. Dow, President and CEO, Acquires Common Shares of 60 Degrees Pharmaceuticals Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SXTP"],"gpt_icon":0},{"id":"2590501450","title":"Geoffrey S. Dow, President and CEO, Acquires Common Shares of 60 Degrees Pharmaceuticals Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2590501450","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590501450?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:40","pubTimestamp":1765546823,"startTime":"0","endTime":"0","summary":"Geoffrey S. Dow, President and CEO of 60 Degrees Pharmaceuticals Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL81q4r6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Geoffrey S. Dow, President and CEO, Acquires Common Shares of 60 Degrees Pharmaceuticals Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTP","BK4007"],"gpt_icon":0},{"id":"2590516579","title":"BRIEF-60 Degrees Pharmaceuticals Announces Expansion Of Arakoda Sales And Marketing In 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516579","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516579?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:06","pubTimestamp":1765458369,"startTime":"0","endTime":"0","summary":"BRIEF-60 Degrees Pharmaceuticals Announces Expansion Of Arakoda Sales And Marketing In 2026Dec 11 (Reuters) - 60 Degrees Pharmaceuticals Inc SXTP.O:60 DEGREES PHARMACEUTICALS ANNOUNCES EXPANSION OF AR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH0L9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTPW","SXTP","BK4007"],"gpt_icon":0},{"id":"2590516832","title":"60 Degrees Pharmaceuticals Announces Expansion of Arakoda® Sales and Marketing in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516832","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516832?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:01","pubTimestamp":1765458071,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH0L9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SXTP"],"gpt_icon":0},{"id":"2590515006","title":"60 Degrees Pharmaceuticals Inc - to Add Clinical Sites for Babesiosis Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2590515006","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590515006?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:01","pubTimestamp":1765458071,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH0L9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SXTP","BK4007","SXTPW"],"gpt_icon":0},{"id":"2586093786","title":"60 Degrees Pharm Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2586093786","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586093786?lang=en_us&edition=fundamental","pubTime":"2025-11-28 19:09","pubTimestamp":1764328140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SXTP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 28, 2025 06:09 ET (11:09 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTP","BK4007"],"gpt_icon":0},{"id":"2585145552","title":"BRIEF-60 Degrees Pharmaceuticals Announces Clinical Site Now Open For Patient Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2585145552","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585145552?lang=en_us&edition=fundamental","pubTime":"2025-11-21 21:26","pubTimestamp":1763731611,"startTime":"0","endTime":"0","summary":"BRIEF-60 Degrees Pharmaceuticals Announces Clinical Site Now Open For Patient EnrollmentNov 21 (Reuters) - 60 Degrees Pharmaceuticals Inc SXTP.O:60 DEGREES PHARMACEUTICALS ANNOUNCES CLINICAL SITE NOW ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nTUA9KLPY7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTPW","SXTP","BK4007"],"gpt_icon":0},{"id":"2585143190","title":"60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2585143190","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585143190?lang=en_us&edition=fundamental","pubTime":"2025-11-21 21:01","pubTimestamp":1763730060,"startTime":"0","endTime":"0","summary":"90-day trial will measure change in general fatigue in patients with chronic babesiosis followingtafenoquine treatmentStudy will run approximately 12 months and enroll up to 100 patientsInternal estim","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/21/3192770/0/en/60-Degrees-Pharmaceuticals-Announces-Clinical-Site-Now-Open-for-Patient-Enrollment-for-the-B-FREE-Chronic-Babesiosis-Study-at-Mount-Sinai-Icahn-School-of-Medicine.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTP","BK4007"],"gpt_icon":0},{"id":"2584600663","title":"60 Degrees Pharmaceuticals Faces Financial Challenges Amid Growth Efforts","url":"https://stock-news.laohu8.com/highlight/detail?id=2584600663","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584600663?lang=en_us&edition=fundamental","pubTime":"2025-11-18 12:05","pubTimestamp":1763438731,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ) has released its Q3 earnings. Here is a breakdown of the information 60 Degrees Pharmaceuticals, Inc. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-faces-financial-challenges-amid-growth-efforts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-faces-financial-challenges-amid-growth-efforts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SXTP","BK4007"],"gpt_icon":0},{"id":"2584617074","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584617074","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584617074?lang=en_us&edition=fundamental","pubTime":"2025-11-17 15:30","pubTimestamp":1763364624,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fate Therapeutics (FATE – Research Report), ALX On...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-fate-therapeutics-fate-alx-oncology-holdings-alxo-and-60-degrees-pharmaceuticals-inc-sxtp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-fate-therapeutics-fate-alx-oncology-holdings-alxo-and-60-degrees-pharmaceuticals-inc-sxtp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","ALX","BK4231","BK4007","BK4581","XBI","BK4080","BK4139","LU0029874061.USD","FATE","HCSG","BK4588","LABU","LU0128526141.USD","SXTP","XLV","BK4585","ALXO"],"gpt_icon":0},{"id":"2583450648","title":"60 Degrees Pharm Coverage Assumed by HC Wainwright & Co. at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2583450648","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583450648?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:58","pubTimestamp":1763125080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SXTP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2025 07:58 ET (12:58 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTP","BK4007"],"gpt_icon":0},{"id":"2583951538","title":"60 Degrees Q3 EPS $(0.66) Beats $(1.21) Estimate, Sales $437.602K Beat $400.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583951538","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583951538?lang=en_us&edition=fundamental","pubTime":"2025-11-14 02:54","pubTimestamp":1763060065,"startTime":"0","endTime":"0","summary":"60 Degrees (NASDAQ:SXTP) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(1.21) by 45.45 percent. This is a 85.81 percent increase over losses of $(4.65) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48845438/60-degrees-q3-eps-0-66-beats-1-21-estimate-sales-437-602k-beat-400-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTP","BK4007"],"gpt_icon":0},{"id":"2583515817","title":"60 Degrees Pharmaceuticals Q3 Operating Expenses USD 2.32 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583515817","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583515817?lang=en_us&edition=fundamental","pubTime":"2025-11-14 02:51","pubTimestamp":1763059860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX40A973:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SXTP"],"gpt_icon":0},{"id":"2583515812","title":"60 Degrees Pharmaceuticals Q3 Net Income USD -2.44 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583515812","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583515812?lang=en_us&edition=fundamental","pubTime":"2025-11-14 02:51","pubTimestamp":1763059860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX40A973:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SXTP","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://60degreespharma.com","stockEarnings":[{"period":"1week","weight":-0.0474},{"period":"1month","weight":-0.3379},{"period":"3month","weight":-0.6605},{"period":"6month","weight":-0.625},{"period":"1year","weight":-0.8786},{"period":"ytd","weight":-0.0114}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0044},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.068},{"period":"1year","weight":0.1339},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is based in Washington, District Of Columbia.","exchange":"NASDAQ","name":"60 degrees pharmaceuticals, Inc.","nameEN":"60 degrees pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"60 degrees pharmaceuticals, Inc.(SXTP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest 60 degrees pharmaceuticals, Inc.(SXTP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"60 degrees pharmaceuticals, Inc.,SXTP,60 degrees pharmaceuticals, Inc.股票,60 degrees pharmaceuticals, Inc.股票老虎,60 degrees pharmaceuticals, Inc.股票老虎国际,60 degrees pharmaceuticals, Inc.行情,60 degrees pharmaceuticals, Inc.股票行情,60 degrees pharmaceuticals, Inc.股价,60 degrees pharmaceuticals, Inc.股市,60 degrees pharmaceuticals, Inc.股票价格,60 degrees pharmaceuticals, Inc.股票交易,60 degrees pharmaceuticals, Inc.股票购买,60 degrees pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"60 degrees pharmaceuticals, Inc.(SXTP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest 60 degrees pharmaceuticals, Inc.(SXTP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}